In this interview, Dr. Gary Pestano and Dr. Prithwish Pal discuss the advantages ddPCR offers in molecular residual disease ...

SAN ANTONIO — A new study strengthens the evidence that pathological complete response (pCR) is a good surrogate marker of longer-term efficacy in the neoadjuvant drug treatment of breast cancer. pCR, ...

Traditionally, test developers have used quantitative PCR (qPCR) to create highly specific laboratory-developed tests (LDTs). However, digital PCR (dPCR) is emerging as the preferred technology for ...

PCR is a mainstay in diagnostics, but whether a sample is collected at a clinic or at home, such tests require sending a sample to a lab and then waiting for results. A new FDA authorized ...

“Neoadjuvant treatment with 12 weeks of THP led to a pCR rate of 64% in patients with early-stage HER2-positive, ER-negative breast cancer at the time of surgery, compared to 33% for those with ...

If conducted every year or every other year, the multi-cancer early detection blood test could help more people survive cancer, researchers reported Thursday in BMJ Open. Adobe stock/HealthDay May 9 ...

Out of the 386 regencies and mayoralties targeted by the Health Ministry, fewer than half are estimated to have public health ...

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A ...